#India #Bengaluru #Bioconjugation #ADC Development #Syngene International

Syngene International Expands Bioconjugation Suite for ADC Development

Syngene International, a leading global contract research, development and manufacturing organization (CRDMO), has announced its plans to enhance its capabilities with the introduction of a new Good Manufacturing Practice (GMP) bioconjugation suite at its commercial biologics facility in Bengaluru, India. This exciting development is aimed at offering fully integrated, end-to-end services for the production and development of antibody-drug conjugates (ADCs), placing Syngene among a select group of CDMOs with comprehensive service offerings in this specialized field.

The addition of this OEB-5 rated bioconjugation suite will not only facilitate monoclonal antibody (mAb) production alongside GMP bioconjugation but will also streamline the ADC development timeline by housing these critical processes under one roof. Given the complexities typically involved in ADC development—which often requires coordination among multiple vendors and locations—Syngene’s single-site solution will significantly diminish supply chain complexities and mitigate potential delays.

Alex Del Priore, Head of LM CDMO at Syngene International, remarked on the advantages of this integrated approach, stating, "The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays. By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing."

The newly established facility is not only poised to support monoclonal antibody production but also advanced conjugation processes that are crucial for a range of highly potent therapeutics. With proven proficiency in handling high-potency payloads and linkers, Syngene is well-equipped to meet the increasing demands of clinical programs and looks forward to further expanding its commercial-scale capabilities in the near future.

Additionally, the bioconjugation suite will feature laboratories designed for process development, analytical characterization, and scale-up services targeting both early- and late-stage programs. This development reinforces Syngene's commitment to delivering agile, science-driven partnerships for biotech and biopharma clients looking to implement ADC programs effectively and efficiently.

With ADCs being one of the fastest-growing segments in cancer treatment, the need for effective and responsive manufacturing partners continues to rise. Syngene's investment in the bioconjugation suite signals its dedication to supporting a robust pipeline of molecules on the verge of entering clinical development, while enhancing its operational excellence and innovation capabilities in this specialized field.

Moreover, for those interested in learning more about Syngene’s latest investment and offerings, the company will be showcasing its advancements at the CPHI Frankfurt event at Ground Level, Hall Number 6, Booth Number C66, where further information will be shared with attendees.

About Syngene

Syngene International Ltd. is a fully integrated research, development, and manufacturing services company, catering to diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. Boasting a dedicated workforce of over 5,600 scientists, Syngene delivers unparalleled scientific excellence, stringent data security, and world-class manufacturing capabilities to enhance time-to-market and reduce the costs associated with innovation. With an impressive 2.5 million square feet of specialized facilities, Syngene collaborates with approximately 400 global clients—including leading biotech firms and multinational giants like BMS, GSK, Zoetis, and Merck KGaA. For additional insights, visit Syngene International.